… Background and Purpose—The role of atrial fibrillation (AF) as a determinant of stroke …
We aimed at evaluating clinical characteristics, care, and outcome of stroke associated with …

… with atrial fibrillation contributing 32,888 person-years of follow-up on warfarin, obtaining
data from clinical databases and validating hemorrhage events using medical record review. …

… We documented an increased incidence of atrial fibrillation detection (risk ratio=2.46; 95% CI,
… In the subgroup analysis, according to study type, atrial fibrillation detection, anticoagulant …

… or paroxysmal AF, sustained atrial flutter, intracardiac thrombus, prosthetic cardiac valve, …
will compare dabigatran etexilate and rivaroxaban, respectively, to aspirin in ESUS patients. …

… The family of NOACs includes dabigatran etexilate, rivaroxaban, apixaban and edoxaban, …
, Non valvular atrial fibrillation VTE treatment Non valvular atrial fibrillation VTE treatment and …

… Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after
total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet 2007 …

… for stroke prevention in atrial fibrillation, treatment of venous … stages of development are
dabigatran etexilate, a direct … the treatment of VTE and prevention of stroke in patients with …

… Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial
fibrillation. … Economic factors associated with antithrombotic treatments for stroke prevention in …

… Other independent predictors of cost included stroke severity, heparin treatment, atrial
fibrillation, male sex, ischemic cardiac disease, and premorbid functional status. …

… : This review discusses the current state of coumarin pharmacogenetics, the evidence from
recent randomized controlled trials and economic evaluations … of coumarin treatment. Current …